FDA Inspection
Avista Pharma Solutions, Inc. dba CambrexAvista Pharma Solutions, Inc. dba Cambrex – FDA Inspection, Jul 3, 2025
Record Details
This FDA Inspection record concerns Avista Pharma Solutions, Inc. dba Cambrex, with an inspection on July 3, 2025, issued by the Atlanta District Office, covering human drugs.
View Company Profile
ID · 8a4208ef-dcad-47c0-9bbd-2ab3cdc26b19
Inspection Facts
- Inspection number
- 1277419
- FDA center
- Human Drugs
Other FDA inspections of Avista Pharma Solutions, Inc. dba Cambrex
3| Date | Classification | Office | Project area |
|---|---|---|---|
| July 17, 2020 | NAI | Center for Drug Evaluation and Research | Drug Quality Assurance |
| October 30, 2012 | NAI | Center for Drug Evaluation and Research | Drug Quality Assurance |
| October 9, 2009 | NAI | Center for Drug Evaluation and Research | Drug Quality Assurance |
Other documents for Avista Pharma Solutions, Inc. dba Cambrex
- FDA Inspection 1128465 - 2020-07-17
- FDA Inspection 805222 - 2012-10-30
- FDA Inspection 636454 - 2009-10-09
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.